CDX-301 (Amgen)

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameCDX-301 (Amgen)
Drug Alias NameFlt3-LrhuFlt3LFlt-3 ligandVaccine-adjuvant-FLT-3-ligandVaccine-adjuvant-Immunex +[8] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionHaematopoiesis stimulantsTyrosine-protein kinase receptor FLT3 stimulants
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityParker Institute For Cancer ImmunotherapyIcahn School Of Medicine At Mount Sinai
Inactive CompaniesCelldex TherapeuticsNational Cancer Institute
Active IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantBreast Neoplasms +[5] 
Inactive IndicationsUveal melanomaSkin MelanomaMyelodysplastic Syndromes +[10] 

Other Information

ATC CodeN/A
Related LinksN/A